Positive data backs Medtronic's Valiant thoracic stent graft for treating degenerative TAA
This article was originally published in Clinica
Executive Summary
The Valiant thoracic stent graft system developed by Medtronic has met all the endpoints in a 160-patient trial. The positive outcome should hopefully help boost market uptake of the product, which was approved by the US FDA only two months ago.